Michael Chang

Michael Chang

Plus aucun poste en cours

73 ans
Health Technology
Consumer Services
Consumer Non-Durables

Profil

Michael N.
Chang
is the founder of Optimer Pharmaceuticals LLC (1998), Pharmanex, Inc. (1994), and OBI Pharma, Inc. (2002).
At Optimer Pharmaceuticals LLC, he held the title of Director from 1998 to 2013.
At Pharmanex, Inc., he held the title of Chief Science Officer, SVP-Research & Development.
At OBI Pharma, Inc., he held the title of Chairman & Spokesman.
Dr. Chang's former jobs include Director-Drug Development Division at Rhone-Poulenc Rorer, Inc., Deputy Director-Pharmaceutical Chemistry at Merck Sharp & Dohme (I.A.) Corp.
(Taiwan), Director at Ansun Biopharma, Inc., Vice President-Pharmaceutical Department at ArQule, Inc., and Chief Scientific Officer at Nu Skin Enterprises, Inc. from 1998 to 2000.
He was also a Partner at Delos Advisors Ltd.
Dr. Chang received a doctorate degree from Brandeis University and an undergraduate degree from Fu Jen Catholic University.

Anciens postes connus de Michael Chang

SociétésPosteFin
Directeur Général 05/05/2010
NU SKIN ENTERPRISES, INC. Directeur Technique/Scientifique/R&D 01/01/2000
Directeur/Membre du Conseil -
Private Equity Investor -
Merck Sharp & Dohme (I.A.) Corp. (Taiwan) Corporate Officer/Principal -
Voir l'expérience en détail de Michael Chang

Formation de Michael Chang

Brandeis University Doctorate Degree
Fu Jen Catholic University Undergraduate Degree

Expériences
Fonctions occupées

Actives

Inactives

Sociétés cotées

Entreprise privées

Voir l'expérience en détail de Michael Chang

Relations

45

Relations au 1er degré

11

Entreprises liées au 1er degré

Homme

Femme

Administrateurs

Exécutifs

Voir le réseau personnel

Sociétés liées

Sociétés cotées2
NU SKIN ENTERPRISES, INC.

Consumer Non-Durables

OBI PHARMA, INC.

Health Technology

Entreprise privées7

Health Technology

Retail Trade

Health Technology

Health Technology

Merck Sharp & Dohme (I.A.) Corp. (Taiwan)

Finance

Health Technology

Voir les connexions sociétés
  1. Bourse
  2. Insiders
  3. Michael Chang